R. Loch Macdonald
CIK 1653008 · Chief Medical Officer · last filed 2026-09-01
R. Loch Macdonald is a Chief Medical Officer who has filed 14 SEC Form 4 insider transactions across 4 companies since 2015. The most recent filing, for GRCE, was dated Sep 1, 2026. Across all open-market trades the lifetime net is −$380.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
EDGE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 300
PRINCETON, NJ 08540
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GRCE | Chief Medical Officer | — | $1.81 | — | $0 | 2 | 2026-09-01 |
| Grace Therapeutics, Inc. (ACST) Delisted | Chief Medical Officer | — | $3.37 | — | $0 | 2 | 2024-05-08 |
| PDSB | Director | 587,729 | $1.06 | $625.9K | $0 | 1 | 2019-03-18 |
| EDGE | Chief Scientific Officer | 28,530 | $52.10 | $1.49M | -$380.4K | 9 | 2018-08-15 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-01 | GRCE | Grant (A) | — | $0 | EDGAR |
| 2025-04-16 | GRCE | Grant (A) | — | $0 | EDGAR |
| 2024-05-08 | Grace Therapeutics, Inc. (ACST) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-07-18 | Grace Therapeutics, Inc. (ACST) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-18 | PDSB | Exer (M) | +10,000 | $0 | EDGAR |
| 2018-08-15 | EDGE | Grant (A) | — | $0 | EDGAR |
| 2018-06-20 | EDGE | Grant (A) | — | $0 | EDGAR |
| 2018-03-22 | EDGE | Sell (S) | −2,500 | -$41.0K | EDGAR |
| 2018-03-21 | EDGE | Sell (S) | −10,000 | -$165.3K | EDGAR |
| 2018-02-22 | EDGE | Sell (S) | −12,500 | -$174.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.